Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
A Single-center, Open-label, Single-dose, Three-period, Fixed Sequence Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042 Soft-Gelatin Capsules Administered Orally to Healthy Adult Participants With Co-administered Agent
NeuroPro Therapeutics, Inc.
8 participants
Sep 29, 2025
INTERVENTIONAL
Conditions
Summary
A Single-center, Open-label, Single-dose, Three-period, Fixed Sequence Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules
Eligibility
Inclusion Criteria6
- Males and females between 19 and 65 years of age, inclusive.
- Body mass index (BMI) of 18 to 35 kg/m2, inclusive, using the following formula: weight (kg)/\[height (m)\]
- A minimum body weight of 50 kg for males and 45 kg for females.
- All females must have a negative serum pregnancy test at Screening and a negative serum pregnancy test upon admission to the clinical research center.
- Females must be of non-child-bearing potential.
- Male participants with female partners of reproductive potential must agree to protocol specifications.
Exclusion Criteria18
- Clinically significant acute illness within 2 weeks prior to Day -1.
- Presence of active or recurring clinically significant cardiovascular, pulmonary, renal, endocrine, hepatic, neurologic, psychiatric, immunologic, hematologic, gastrointestinal, or metabolic disease requiring medical treatment.
- Presence of an active malignancy or a malignancy of any type within the past 5 years, other than squamous cell or basal cell carcinoma of the skin.
- Clinically significant acute or chronic infection or known inflammatory condition.
- Personal or family history of long QT syndrome.
- History or evidence of adverse symptoms associated with phlebotomy or blood donation
- History of clinically significant orthostatic hypotension or any vasovagal syncope.
- Plans for surgery or other medical procedures during the study.
- Clinically significant past or current medical or surgical history that could interfere with treatment.
- Participation in an investigational drug or device study within 30 days or five half-lives, whichever is longer \[90 days for biologics\], prior to dosing.
- Presence of clinically significant illness or abnormality on physical examination.
- Presence of clinically significant ECG abnormality at Screening, including any QT interval corrected for heart rate (QTc) using Fridericia formula (QTcF) ≥470 msec.
- Ongoing liver disease or unexplained liver function test (LFT) elevations, defined as alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transferase (GGT), or alkaline phosphatase (ALP) greater than the upper limit of normal (ULN).
- Any other clinically significant laboratory results, as judged by the investigator.
- History or presence of clinically significant hypersensitivity (e.g. systemic or cutaneous) as judged by the investigator to NPT 2042.
- History of substance abuse or current use of any drugs of abuse.
- Blood donation of \>500 mL or more within 56 days prior to Day -1.
- Any other reason that, in the opinion of the investigator, would render the participant unsuitable for study enrollment.
Interventions
In Period 1 Day 1, participants will receive Formulation 1 in a fasted state (Treatment A).
Following a 3-day wash out, in Period 2 Day 1, participants will receive Formulation 2 in a fasted state (Treatment B).
Following a 4-day wash out, in Period 3 Day 1, participants will receive Formulation 2 in a fasted state with co-administered agent (Treatment C).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07222878